Gilead Sciences stock heads into Denver with new liver data
Published on 11/03/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLiver pipeline enters key conference
- Gilead will present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta.
- The program includes late-breaking Phase 3 findings for Livdelzi and long-term Hepcludex analyses.
- Presentations will address treatment response, patient symptoms, testing gaps and disease management.
Gilead Sciences will present new clinical and real-world evidence on rare liver diseases at The Liver Meeting 2026 in Denver from Thursday, November 5, through Monday, November 9. The company announced the program on October 22 in a Gilead Investor Relations announcement.
The scientific program comprises 21 accepted abstracts covering primary biliary cholangitis, or PBC, and chronic hepatitis delta virus infection. The agenda gives investors a view of how Gilead is extending its liver portfolio beyond established HIV medicines, although the conference presentations remain an upcoming event rather than a reported commercial outcome.
Livdelzi data target PBC treatment
The late-breaking Phase 3 IDEAL presentation will examine whether Livdelzi, also known as seladelpar, supports composite alkaline phosphatase normalization in adults with PBC whose alkaline phosphatase levels are between 1 and 1.67 times the upper limit of normal. The participants were receiving ursodeoxycholic acid or could not tolerate it.
Gilead also plans to present long-term safety and efficacy findings from the ASSURE study, including follow-up of up to five years. Additional work will address fatigue, treatment eligibility, escalation to second-line therapy, patient quality of life, treatment adherence and healthcare use. These topics matter commercially because durable response and tolerability can influence prescribing and long-term use in a chronic disease.
The company said the IDEAL results will be presented orally on Sunday, November 8. The long-term ASSURE and related PBC analyses are scheduled for poster sessions on Thursday, November 5, while the fatigue analysis is also scheduled for November 8.
Hepcludex program broadens evidence
For chronic hepatitis delta, Gilead will present 96-week efficacy findings on the combined virologic and biochemical response associated with Hepcludex, also known as bulevirtide-gmod. A separate 48-week analysis will examine clinically significant portal hypertension and its impact in people receiving treatment.
The HDV program also includes research on on-treatment ALT flares, fibrosis testing, disease progression and the relationship between post-treatment HDV RNA measures and longer-term outcomes. U.S. real-world studies will examine low testing rates and the burden of advanced liver disease. The presentations could help clarify the treatment pathway for a disease that is difficult to diagnose and can progress rapidly, but they do not by themselves establish a new regulatory approval or a commercial forecast.
Gilead Sciences stock traded at 152.28 euros on Lang & Schwarz at 13:41 CET on Tuesday, November 3, 2026. The real-time quote of Gilead Sciences stock provides the latest trading indication.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Home ticker: GILD
- Trading venue: Lang & Schwarz
- Price: 152.28 euros at 13:41 CET on November 3, 2026
Broader market conditions remain relevant for pharmaceutical valuations; see current S&P 500 market coverage.
The next defined catalyst is the Liver Meeting program, with key Livdelzi findings scheduled for November 8 and several Hepcludex analyses scheduled for November 7. Further updates will depend on the full presentations and on whether the evidence changes expectations for long-term adoption. More news and analyses on Gilead Sciences stock.
